Condition: Pneumonia, Community-Acquired · Bacterial Pneumonia · Sponsor: Dr. Md. Alimur Reza
The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.
This description comes directly from the study's public registry record.
Prof. Khan Abul Kalam Azad, MBBS, FCPS, MD(Med), FACP(USA) · +880-1727271414 · prof.kakazad@gmail.com
Always discuss trial participation with your own doctor first.
| Popular Medical College & Hospital | Dhaka, Dhaka Division, Bangladesh | Recruiting |
| Shaheed Suhrawardy Medical College & Hospital | Dhaka, Dhaka Division, Bangladesh | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06804096